Could Molnupiravir Be the First-Line Alternative Oral Antiviral Agent for COVID-19 Patients at High Risk?
J Korean Med Sci
.
2024 Feb 19;39(6):e74.
doi: 10.3346/jkms.2024.39.e74.
Author
Ji Yong Lee
1
Affiliation
1
Division of Infectious Disease, Department of Internal Medicine, Gumdan Top Hospital, Incheon, Korea. godjong454@naver.com.
PMID:
38374633
PMCID:
PMC10876427
DOI:
10.3346/jkms.2024.39.e74
No abstract available
Publication types
Editorial
MeSH terms
Antiviral Agents / therapeutic use
COVID-19*
Cytidine / analogs & derivatives*
Humans
Hydroxylamines
Substances
molnupiravir
Hydroxylamines
Cytidine
Antiviral Agents